Revalesio Corporation is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating the use of RNS60 may have beneficial effects on cardiac damage associated with heart attacks. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida.

In this pilot, pre-clinical ischemia/reperfusion pig model of heart attacks, RNS60 reduced the mortality and reduced signs of heart tissue damage and overall inflammation in male pigs. In both male and female pigs, RNS60 lowered troponin levels (a marker of heart damage) and normalized ECG (electrocardiogram) tracings. Data from this study will be presented via poster session (#17400) on November 14th.. These results indicate that RNS60 may have promise in the treatment of reperfusion injury following a heart attack.

In addition to the data being presented at the AHA meeting, Revalesio has successfully completed a first-in-man clinical trial of RNS60 using intravenous (I.V.) dosing as a first step in evaluating the use of RNS60 for the treatment of acute myocardial infarctions (AMI/heart attacks). The study, conducted in conjunction with Quintiles in Overland Park, Kansas, met all safety endpoints and supports the unparalleled safety profile of RNS60.

This data indicates RNS60 may provide an important new treatment option for patients suffering from AMI. Further research of RNS60 is being conducted in pre-clinical models and a Phase II clinical trial in patients suffering from AMI is development for 2012.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Bruce Buskirk
253-926-5567
contact@revalesio.com.

Revalesio Corporation has successfully completed a first-in-man clinical trial of RNS60 using intravenous (I.V.) dosing. The study, conducted in conjunction with Quintiles in Overland Park, Kansas, met all safety endpoints and supports the unparalleled safety profile of RNS60 as a novel anti-inflammatory therapeutic.

The study evaluated continuous I.V. administration of RNS60 in healthy subjects in a 7-day dose escalation study. Infusion rates were increased every 48 hours on rates of 100cc/hr, 150cc/hr, and 200cc/hr. All safety end-points of the study were met. Further testing of immune markers in the subject’s blood and urine showed no abnormalities of immune function in any of the subjects.

The data from this study enables Revalesio to advance into Phase II clinical studies evaluating the novel anti-inflammatory activity of RNS60. Revalesio is developing RNS60 as a novel, first-in-class anti-inflammatory therapeutic for treating serious disease. This Phase I I.V. study supports the excellent safety profile demonstrated in the Phase I inhalation study completed in mid-2011.

Revalesio is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating the use of RNS60 may have beneficial effects on cardiac damage associated with acute myocardial infarction. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida. Data from this study will be presented via poster session (#17400) on November 14th.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Bruce Buskirk
253-926-5567
contact@revalesio.com

Tacoma, WA – Revalesio Corporation will present clinical efficacy and safety data for RNS60 at the annual ACAAI meeting in Boston, November 3-8. ACAAI (American College of Allergy, Asthma and Immunology) is a professional association with more than 5,000 members devoted to the specialty of allergy and immunology.

In this first in man asthma study, RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the Phase I study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma. These findings demonstrate that RNS60, a novel product containing charge-stabilized nanostructures (CSN), is safe and has therapeutic benefit in human subjects suffering from asthma.

These data suggest CSN solutions provide an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases. The therapeutic activity seen in Revalesio’s RNS60 is a promising alternative to steroid treatments currently used to control asthma exacerbations.

Revalesio has initiated a further clinical investigation of RNS60 in asthma in combination with the inhaled steroid budesonide. The study will evaluate RNS60 in combination with high and low dose budesonide over a 28 day period to evaluate the effect of the paired therapy on FEV1 scores and other respiratory parameters.

About RNS60

Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines and adhesion molecules. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation

Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is pioneering the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Bruce Buskirk
253-926-5567
contact@revalesio.com.

Revalesio, a pioneering biotechnology company based in Tacoma, recently signed an 18-month contract with the Katze lab at the University of Washington to bring hope to sufferers of influenza, HIV and hepatitis C.

(Revalesio said it does not disclose financial terms of research agreements.)

“We are excited to work with Dr. Katze, a world-class researcher in his field,” said Richard Watson, director of clinical science at Revalesio.

Michael Katze, a professor of microbiology, director of the Center for Systems and Translational Research on Infectious Disease and associate director of the Washington National Primate Research Center, runs a lab of 35 researchers focused on systems biology approaches to define and model virus-host interactions and the varied strategies used by viruses to evade cellular defense mechanisms.

The lab studies a wide range of viral pathogens, including hepatitis C, influenza, ebola, West Nile, SARS-associated coronavirus, herpes simplex virus and human and simian immunodeficiency viruses.The agreement with Revalesio will test whether the firm’s anti-inflammatory technology has an effect on influenza, HIV and hepatitis C viruses. Virus infection will be a new area of exploration for Revalesio.

Katze said that the systems biology approaches his lab uses allows researchers to gain a more global view of the complex interactions that occur when a cell encounters a pathogen. He said these approaches hold great potential to help elucidate the underlying mechanisms by which therapeutic agents work to combat a pathogen and thus impact the disease process.

Revalesio has partnered with leaders in biomedical research around the world to develop its anti-inflammatory technology for the treatment of a wide range of inflammatory diseases such as asthma, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and cardiovascular disease using an approach called charge-stabilized nanostructure technology.

Revalesio is a pioneer in the novel use of charge-stabilized nanostructures as therapeutic agents. According to researchers, charge-stabilized nanostructures alter a cell’s ability to transmit signals through voltage-gated ion channels and other voltage-sensing proteins. Through these effects on the cell membrane, charge-stabilized nanostructures reduce inflammatory signals that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

Revalesio is currently exploring therapeutic applications for asthma, multiple sclerosis, Alzheimer’s, Parkinson’s and cystic fibrosis. The therapeutics for asthma and cardiovascular disease are now in clinical trials.

“Our motivation is to bring hope to people suffering from disease,” said Watson.

Watson said Revalesio wanted to work with the Katze lab because of the lab’s track record of applying cutting edge technologies in combination with traditional virology techniques to understand biological response.

Katze said his lab is looking forward to exploring Revalesio’s approach.

“The therapeutics that they have under development are very promising in many disease areas,” he said. “Our hope is that this collaboration will expedite the development of a promising new therapy.”

Revalesio has also signed a master agreement with UW, which will facilitate future collaborations between the University and the biotech firm.

Link to University of Washington press release.
http://www.washington.edu/news/articles/uws-katze-lab-signs-18-month-contract-to-research-novel-approaches-to-viral-diseases

Date: April 14, 2011

Read article by Dr. Richard Watson on Xconomy.com

Tacoma, WA – Revalesio Corporation announced today that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San Francisco on March 18-22.

AAAAI is the largest professional organization in the United States devoted to the specialty of allergy and immunology. It has nearly 6,500 members in the United States, Canada and 60 other countries.

Revalesio will present findings that demonstrate the novel anti-inflammatory activity of charge-stabilized nanostructures both in a preclinical model of allergic asthma and in cell culture experiments. These data suggest that Revalesio’s novel therapeutic RNS60 provides an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases.

In the preclinical model of asthma, RNS60 showed significant efficacy in the reduction of key inflammatory cytokines, including interleukin-6, interleukin-4, tumor necrosis factor-α (TNF-α), eotaxin and other cytokines known to be drivers of asthma. In addition to reducing inflammatory cytokines, RNS60 improved respiratory parameters compared to treatment with the inhaled corticosteroid budesonide.

The presented cell culture studies demonstrate the anti-inflammatory activity of RNS60 by decreasing the production of key inflammatory mediators of asthma, including C-C chemokine receptor type 3 (CCR3) and interleukin-8. The research also demonstrates that RNS60 exerts its effects through the modulation of whole cell conductance.

RNS60 is currently in a Phase I/IIa clinical trial at Stanford University for allergic asthma.

About charge-stabilized nanostructures (CSN)

Revalesio has pioneered the novel use of charge-stabilized nanostructures to alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the expression of G protein-coupled receptors and the secretion of cytokines, chemokines and adhesion molecules. These changes to whole cell conductance reduce inflammatory signals that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation:

Revalesio is a pioneering biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is pioneering the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:

Bruce Buskirk

253-926-5567

contact@revalesio.com.

TACOMA, Wash. – Revalesio Corporation and Rush University will present research on the use of RNS60 at the American Society of Neurochemistry (ASN) meeting in St. Louis.

Researchers at Rush University Medical Center demonstrated profound anti-inflammatory activity of RNS60, a biologically active fluid possessing charge-stabilized nanostructures (CSN), in models of Alzheimer’s and Parkinson’s diseases. These findings establish RNS60 as a strong candidate for further development as a novel therapeutic in neurodegenerative diseases.

The ASN’s annual conference, scheduled for March 16-18, brings together molecular and cellular neuroscientists to share the latest research and advance the field of neurology.

RNS60 demonstrates “protective” effect in Alzheimer’s disease and Parkinson’s disease

Research conducted at Rush University revealed that RNS60 protected cultured cells against beta amyloid-induced cell death, a known driver of Alzheimer’s disease. Since RNS60 is unique in its anti-inflammatory activity, these results identify a novel approach to inhibiting neuronal damage from beta amyloid and potentially a new approach for treating Alzheimer’s disease. Revalesio will present further research demonstrating the prevention of tau hyperphosphorylation – another key factor in the progression of Alzheimer’s disease – at the American Academy of Neurology meeting April 9-16 in Honolulu, HI.

At the ASN conference, Revalesio will also present data related to Parkinson’s disease. In a neurotoxin model of the disease, RNS60 protected neurons, restored dopamine levels, and improved the motor function of Parkinson’s affected mice. These results suggest a potential therapeutic benefit of RNS60 for patients suffering from Parkinson’s disease.

About charge-stabilized nanostructures (CSN)

Revalesio has pioneered the novel use of charge-stabilized nanostructures to alter whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the expression of G protein-coupled receptors and the secretion of cytokines, chemokines and adhesion molecules. These changes to whole cell conductance reduce inflammatory signals that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation:

Revalesio is a pioneering biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is pioneering the use of CSN in neuro-inflammatory, respiratory, cardiovascular, and other inflammatory diseases. For more information, please visit: revalesio.com.

Press Contact:

Bruce Buskirk

253-926-5567

contact@revalesio.com.

Date: October 20, 2010

TACOMA, Wash. – Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

“We’re developing a new technology that has novel anti-inflammatory effects applicable to a broad range of diseases,” said Dr. Richard Watson, director of Clinical Science at Revalesio, based in Tacoma. “Working with PBS-Bio, we want to further investigate how our technology alters cell survival in a number of different cancer lines, specifically looking at the connection of specific signaling pathways to inflammatory processes and proliferation signaling in oncology.”

A biomedical company based in Tacoma, Revalesio is advancing an entirely new class of therapeutics that disrupts inflammatory pathways. The company’s pioneering research, including an ongoing clinical trial for asthma, shows strong clinical efficacy with a remarkable lack of toxicity.
In addition to its work with PBS-BIO, Revalesio is developing treatments for cardiovascular disease, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and other inflammatory mediated diseases.
PBS-Bio will provide Revalesio with unique real-time looks at how its therapeutics actually work over time within cellular pathways — the so-called mechanisms of action, said Dr. Edward Smith, co-founder and CEO of PBS-Bio, based in Mesa, Ariz.

The analysis will support Revalesio’s efforts to develop novel therapeutic candidates containing “charged-stabilized nanostructures” to prevent inflammation and treat inflammatory mediated diseases without inhibiting normal cellular functions.

Charge-stabilized nanostructures (CSNs) are aqueous-based nano-bubble cores surrounded by a stable molecular scaffolding. CSNs interact with cells, specifically naïve immune cells, altering the surface of the cell membrane and preventing unwanted downstream cellular activity that causes inflammation.

“The charged-stabilized nanostructure is a platform from which we can create a variety of products as combination therapies or standalone therapeutics,” Dr. Watson said.

PBS-Bio is helping companies develop therapies against a variety of cancers. Most new cancer drugs fail in late-stage studies, and it can take as much as $1 billion and more than a decade to bring the drugs to market.

About Revalesio:

Revalesio Corporation is a biomedical development company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, the company is advancing an entirely new class of therapeutics that disrupts inflammatory pathways and protects cellular function. With leading research partners from around the world, Revalesio is targeting neuro-inflammatory, respiratory, cardiovascular and other inflammatory mediated diseases. For more information about Revalesio, visit www.revalesio.com.

Press Contact:

Bruce Buskirk

253-926-5567

contact@revalesio.com.

About PBS-Bio:

Predictive Biomarker Sciences Inc. (PBS-Bio) is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. It is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen). The PBS-Bio/TGen collaborative team includes: Dr. Michael Bittner, a biologist, Co-Director of TGen’s Computational Biology Division, and Principal Investigator at TGen for the PBS-Bio technology; Dr. Edward Dougherty, an electrical engineer and the other Co-Director of TGen’s Computational Biology Division; and Dr. Edward Smith, a medical doctor, an adjunct faculty member of TGen, and co-founder and CEO of PBS-Bio. The three began their collaborations while working under TGen President and Research Director Dr. Jeffrey Trent when Dr. Trent was the Scientific Director of the National Human Genomics Research Institute in Bethesda, Md. Their professional relationships continued after TGen was founded in Phoenix in 2002. For more information, please visit: pbs-bio.com.

Press Contact:

Dr. Edward Smith, M.D.

President and CEO

602-418-9300

edsmith@pbs-bio.com.

MESA, Ariz. – Oct. 20, 2010 – In an industry that faces increasing challenges in delivering new drugs to patients, Predictive Biomarker Sciences (PBS-Bio) today announced three new contracts aimed at bringing new medicines to the marketplace.

PBS-Bio said it is helping more companies develop therapies against a variety of cancers. Most new cancer drugs fail in late-stage studies, and it can take as much as $1 billion and more than a decade to bring the drugs to market.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio’s three new pharmaceutical collaborators are:

These three small pharmaceutical companies are in addition to four collaborations in progress between PBS-Bio and four large pharma groups, said Dr. Edward Smith, co-founder and CEO of PBS-Bio, which is a privately held, Mesa-based for-profit corporation.

“We feel that we have reached critical momentum for the growth of PBS-Bio,” said Dr. Smith. “The pharmaceutical industry is failing in their efforts to bring new cancer drugs to patients with only two drugs approved in 2009, and only two so far this year. The problems are empty pipelines, and outdated methods of drug discovery and development. Pharmaceutical companies are now seeing the value of the PBS-Bio dynamic technology to help bring more new cancer drugs to market faster and cheaper.”

In each case, connections to PBS-Bio were made through scientific networks involving the Translational Genomics Research Institute (TGen), a Phoenix-based biomedical research facility.

And in each case, PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways — the so-called mechanisms of action.

ENDECE

Rather than focusing on a single target or mutation, ENDECE’s approach is to identify key molecular switches that prevent tumors from growing out of control.

“We previously identified a primary mechanism of action for how NDC-1308 kills tumor cells. However, the PBS-Bio technology will validate that mechanism and enable us to observe, in real time, the temporal order of changes for components of the pathways that control cancer cell growth,” said James Yarger, President and CEO of ENDECE. “In addition, we may obtain data showing the impact, both positive and negative, of NDC-1308 on other cellular pathways. With current technology, we have not been able to identify the temporal order of events.”

By working with PBS-Bio, Yarger said, his company also hopes to determine which cancer patients might be the best candidates for the drug and gain an understanding of what current cancer drugs, if any, would be appropriate candidates for combination drug therapies.

“Our bodies fight cancer cells every day, and in general our bodies do it very, very well. However, the appearance of cancerous tumors signifies uncontrolled cancer cell growth and proliferation. When the body’s control over some of these pathways are lost, the cancer cells can grow out of control,” Yarger said. “ENDECE’s focus is on novel therapies that enhance the body’s natural control over cancer cell growth.”

Although initially focused on lung and pancreatic cancer, Yarger said, “Our data supports the notion that NDC-1308 may control the growth of many kinds of aggressively growing cancers. We hope to further verify this data with PBS-Bio’s technology.”

Revalesio

Revalesio is targeting inflammation associated with various inflammatory mediated diseases, including cancer, through the creation of charged-stabilized nanostructures, or CSNs.

CSNs are aqueous based nano-bubble cores surrounded by an ionic scaffolding stabilized with free energy. CSNs interact with cells, specifically naïve immune cells, altering the surface of the cell membrane and preventing unwanted downstream cellular activity that causes inflammation.

“We’re developing a new technology that has novel anti-inflammatory effects applicable to a broad range of diseases,” said Dr. Richard Watson, Director of Revalesio’s Clinical Science. This technology is under development for the treatment of asthma, cardiovascular disease, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and other inflammatory mediated diseases.

“The charged-stabilized nanostructure is a platform from which we can create a variety of products as combination therapies or standalone therapeutics,” Dr. Watson said. “Working with PBS-Bio, we want to see how our technology alters cell-survival in a number of different cancer lines, specifically looking at the connection of specific signaling pathways to inflammatory processes and proliferation signaling in oncology.”

Unibioscreen

At hospitals in Belgium and the Netherlands, Unibioscreen has begun phase 1 clinical trials — first in human tests — with a drug called UNBS1450.

The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of an African plant called Calotropis procera. Pre-clinical tests have shown that UNBS1450 is very effective against various tumor types.

Unibioscreen CEO Christiane Verhaegen said the company wants to further decipher the mechanism of action of this novel drug candidate, in parallel with the ongoing clinical Phase I trial, to optimize the dose and schedule for the further development stages.

“This is a unique compound, that has shown to be very potent in pre-clinical tests. It is crucial for us to do the biomarker work with PBS-Bio, as this work helps us to get a more in-depth understanding of the mechanism and to define the most effective patient treatment,” Verhaegen said.

About ENDECE LLC

ENDECE is a privately held, drug development company focused on first-in-class therapeutics for cancer. ENDECE’s core business relies on the in-house rational design of new chemical entities that control molecular “switches” which impact cancer cell growth. The company plans to take its lead candidate into the clinic in 2011. ENDECE has filed multiple composition-of-matter and use patents on its compounds. ENDECE is privately held and has raised over $13 million dollars from private investors. Please visit: www.endece.com.

Press Contact:

James Yarger, Ph.D.

Chief Executive Officer and President

1001 West Glen Oaks Lane

Suite 105B

Mequon, WI 53092

262-240-9690

james.yarger@endece.com

About Revalesio

Revalesio Corporation is a biomedical development company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, the company is advancing an entirely new class of therapeutics that disrupts inflammatory pathways and protects cellular function. With leading research partners from around the world, Revalesio is targeting neuro-inflammatory, respiratory, cardiovascular and other inflammatory mediated diseases. For more information about Revalesio, visit www.revalesio.com.

Press Contact:

Bruce Buskirk

253-926-5567

contact@revalesio.com

About Unibioscreen

Unibioscreen is a private Belgian specialist oncology company focused on innovative “first-in-class” oncology therapeutics. Unibioscreen has successfully discovered, patented and developed a drug candidate currently in clinical trials in cancer patients. Unibioscreen built its competitive edge on exploiting through hemi-synthesis the structure activity relationship (SAR) of natural product chemistry and through development and use of unique technologies and demanding orthotopic models of cancer. For more information, visit: www.unibioscreen.com.

Press Contacts:

Christiane Verhaegen, CEO

+32 476 98 10 78

About PBS-Bio

Predictive Biomarker Sciences Inc. (PBS-Bio) is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. It is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen). The PBS-Bio/TGen collaborative team includes: Dr. Michael Bittner, a biologist, Co-Director of TGen’s Computational Biology Division, and Principal Investigator at TGen for the PBS-Bio technology; Dr. Edward Dougherty, an electrical engineer and the other Co-Director of TGen’s Computational Biology Division; and Dr. Edward Smith, a medical doctor, an adjunct faculty member of TGen, and co-founder and CEO of PBS-Bio. The three began their collaborations while working under TGen President and Research Director Dr. Jeffrey Trent when Dr. Trent was the Scientific Director of the National Human Genomics Research Institute in Bethesda, Md. Their professional relationships continued after TGen was founded in Phoenix in 2002. For more information, please visit: pbs-bio.com.

Press Contact:

Dr. Edward Smith, M.D.

President and CEO

602-418-9300

edsmith@pbs-bio.com